

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 44

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996*.

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 44

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996*.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 44

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996*.

Proposed INN
(Latin, English, French, Spanish)

Chemical name or description: Action and use: Molecular formula
Chemical Abstracts Service (CAS) registry number: Graphic formula

DCI Proposée

Nom chimique ou description: Propriétés et indications: Formule brute
Numéro dans le registre du CAS: Formule développée

DCI Propuesta

Nombre químico o descripción: Acción y uso: Fórmula empírica
Número de registro del CAS: Fórmula desarrollada

adalimumabum

adalimumab

immunoglobulin G 1 (human monoclonal D2E7 heavy chain anti-human tumor necrosis factor), disulfide with human monoclonal D2E7k-chain, dimer

adalimumab

immunoglobuline G1, anti-(facteur a de nécrose tumorale humain) (chaîne lourde de l'anticorps monoclonal humain D2E7), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal humain D2E7

adalimumab

inmunoglobulina G1 (anti-factor α de necrosis tumoral humano), dímero del disulfuro de la cadena pesada D2E7 monoclonal humana con la cadena κ D2E7 monoclonal humana

adrogolidum

adrogolide

(5a*R*,11b*S*)-4,5,5a,6,7,11b-hexahydro-2-propylbenzo[*f*]thieno[2,3-*c*]quinoline-9,10-diol diacetate (ester)


adrogolide

diacétate de (5a*R*,11b*S*)-2-propyl-4,5,5a,6,7,11b-hexahydrobenzo[*f*]thieno=[2,3-*c*]quinoléine-9,10-diyle

adrogolida

diacetato (éster)de (5a*R*,11b*S*)-4,5,5a,6,7,11b-hexahidro-2-propilbenzo=[*f*]tieno[2,3-*c*]quinolina-9,10-dilo

C₂₂H₂₅NO₄S



alemncinalum


alemncinal

8,9-didehydro-*N*-demethyl-9-deoxo-4'',6,12-trideoxy-6,9-epoxy-*N*-ethylerythromycin

alemncinal

(2*R*,3*S*,4*R*,5*R*,8*R*,9*S*,10*S*,11*R*,12*R*)-5-éthyl-11-[[3-(éthylméthylamino)-3,4,6-tridésoxy- β -D-xylohexopyranosyl]oxy]-3-hydroxy-2,4,8,10,12,14-hexaméthyl-9-[(3-*C*-méthyl-3-*O*-méthyl-2,4,6-tridésoxy- α -L-erythro-hexopyranosyl]oxy]-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-én-7-one

alemcinal

8,9-dideshidro-*N*-desmetil-9-desoxo-4'',6,12-tridesoxi-6,9-epoxi-*N*-etilertromicina $C_{38}H_{67}NO_{10}$ 

altiniclinum

altinicline


(-)-5-ethynilnicotine

altinicline

(-)-3-éthynyl-5-[(2*S*)-1-méthylpyrrolidin-2-yl]pyridine

altiniclina

(-)-5-etinilnicotina

 $C_{12}H_{14}N_2$ 

amiglumidum


amiglumide

(R)-4-(2-naphthamido)-*N,N*-dipentylglutaramic acid

amiglumide

acide (4*R*)-5-(dipentylamino)-4-[(naphthalén-2-ylcarbonyl)amino]-5-oxopentanoïque

amiglumida

(R)-4-(2-naftamido)-*N,N*-dipentilglutarámico $C_{26}H_{36}N_2O_4$ 

anispermusum


anispermus

[(6-guanidinohexyl)carbamoyl]methyl 4-[[[(*R*)-3-aminobutyl]amino]butyl]=
carbamate

anispermus

[4-[[[(3*R*)-3-aminobutyl]amino]butyl]carbamate de
2-[(6-guanidinohexyl)amino]-2-oxoéthyle

anispermus

[4-[[[(*R*)-3-aminobutyl]amino]butyl]carbamato de
[(6-guanidinohexil)carbamoil]metilo $C_{18}H_{39}N_7O_3$ **ataquimastum**


ataquimast

1-ethyl-3-(methylamino)-2(1*H*)-quinoxalinone

ataquimast

1-éthyl-3-(méthylamino)quinoxalin-2(1*H*)-one

ataquimast

1-etil-3-(metilamino)-2(1*H*)-quinoxalinona $C_{11}H_{13}N_3O$ **axitiromum**


axitirome

ethyl (±)-4'-[[α-(*p*-fluorophenyl)-α,4-dihydroxy-*m*-tolyl]oxy]-
3',5'-dimethyloxanilate

axitirome

[[4-[3-[(*RS*)-(4-fluorophényl)hydroxyméthyl]-4-hydroxyphénoxy]-
3,5-diméthylphényl]amino]oxoacétate d'éthyle

axitiromo



(±)-4'-[[α-(*p*-fluorofenil)-α,4-dihidroxi-*m*-tolil]oxi]-3',5'-dimetiloxanilato de etilo $C_{25}H_{24}FNO_6$ and enantiomer
et énantiomère
y enantiómero

bilastinum

bilastine *p*-[2-[4-[1-(2-ethoxyethyl)-2-benzimidazolyl]piperidino]ethyl]- α -methylhydratropic acid

bilastine acide 2-[4-[2-[4-[1-(2-éthoxyéthyl)-1*H*-benzimidazol-2-yl]pipéridin-1-yl]éthyl]phényl]-2-méthylpropanoïque


bilastina ácido *p*-[2-[4-[1-(2-etoxietil)-2-bencimidazolil]piperidino]etil]- α -metilhidratrópico

**binetrakinum**

binetrakin interleukin 4 (human)

binétrakine interleukine 4 humaine



binetrakina interleuquina 4 (humana)

**cangrelorum**

cangrelor *N*-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with (dichloromethylene)diphosphonic acid

cangrélor monoanhydride dichlorométhylènediphosphonique *N*-[2-(méthylsulfanyl)éthyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]-5'-adénylique

cangrelor monoanhidrido del ácido *N*-[2-(metiltio)etil]-2-[(3,3,3-trifluoropropil)tio]-5'-adenílico con ácido (diclorometileno)difosfónico

**cetuximabum**

cetuximab

immunoglobulin G 1 (human-mouse monoclonal C225 γ 1-chain anti-human epidermal growth factor receptor), disulfide with human-mouse monoclonal C225 κ -chain, dimer

cétuximab

immunoglobuline G1, anti-(récepteur du facteur de croissance humain de l'épiderme) (chaîne γ 1 de l'anticorps monoclonal chimérique homme-souris C225), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal chimérique homme-souris C225

cetuximab

inmunoglobulina G 1, anti-(receptor del factor humano de crecimiento de la epidermis)(cadena γ 1-del anticuerpo monoclonal quimérico hombre-ratón C225), dímero del disulfuro con la cadena κ del anticuerpo monoclonal quimérico hombre-ratón C225

cilomilastum

cilomilast



cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylic acid

cilomilast

acide *cis*-4-cyano-4-[3-(cyclopentyloxy)-4-méthoxyphényl]cyclohexanecarboxylique

cilomilast

ácido *cis*-4-ciano-4-[3-(ciclopentiloxi)-4-metoxifenil]ciclohexanocarboxílico

**conivaptanum**

conivaptan


4"-[(4,5-dihydro-2-methylimidazo[4,5-*d*][1]benzazepin-6(1*H*)-yl)carbonyl]-2-biphenylcarboxanilide

conivaptan

N-[4-[(2-méthyl-4,5-dihydroimidazo[4,5-*d*][1]benzaépin-6(1*H*)-yl)carbonyl]phényl]biphényle-2-carboxamide

conivaptán

4"-[(4,5-dihidro-2-metilimidazo[4,5-*d*][1]benzazepin-6(1*H*)-il)carbonil]-2-bifenilcarboxanilida

$C_{32}H_{26}N_4O_2$ **crobenetinum**


crobenetine

(2*R*,6*S*)-3-[(2*S*)-2-(benzyloxy)propyl]-1,2,3,4,5,6-hexahydro-6,11,11-trimethyl-2,6-methano-3-benzazocin-10-ol

crobenétine

(2*R*,6*S*)-3-[(2*S*)-2-(benzyloxy)propyl]-6,11,11-triméthyl-1,2,3,4,5,6-hexahydro-2,6-méthano-3-benzazocin-10-ol

crobenetina

(2*R*,6*S*)-3-[(2*S*)-2-(benciloxi)propil]-1,2,3,4,5,6-hexahidro-6,11,11-trimetil-2,6-metano-3-benzazocin-10-ol $C_{25}H_{33}NO_2$ **cystinum**

cystine


L-cystine

cystine

L-cystine

cistina

L-cistina

 $C_6H_{12}N_2O_4S_2$ **darusentanum**

darusentan


(±)-(S)-2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-3-methoxy-3,3-diphenylpropionic acid

darusentan

(±)-acide (2*S*)-2-(4,6-diméthoxypyrimidin-2-yloxy)-3-méthoxy-3,3-diphénylpropanoïque

darusentán

ácido (±)-(S)-2-[(4,6-dimetoxi-2-pirimidinil)oxi]-3-metoxi-3,3-difenilpropiónico

$C_{22}H_{22}N_2O_6$ **donitriptanum**


donitriptan

1-[[[3-(2-aminoethyl)indol-5-yl]oxy]acetyl]-4-(*p*-cyanophenyl)piperazine

donitriptan

1-[2-[[[3-(2-aminoéthyl)-1*H*-indol-5-yl]oxy]acétyl]-4-(4-cyanophényl)piépérazine

donitriptán

1-[[[3-(2-aminoetil)indol-5-il]oxi]acetil]-4-(*p*-cianofenil)piperazina $C_{23}H_{25}N_5O_2$ **doxercalciferolum**


doxercalciferol

(5*Z*,7*E*,22*E*)-9,10-secoergosta-5,7,10(19),22-tetraene-1 α ,3 β -diol

doxercalciférol

(5*Z*,7*E*,22*E*)-9,10-sécoergosta-5,7,10(19),22-tétraène-1 α ,3 β -diol

doxercalciferol

(5*Z*,7*E*,22*E*)-9,10-secoergosta-5,7,10(19),22-tetraeno-1 α ,3 β -diol $C_{28}H_{44}O_2$ **emfilerminum**

emfilermin

leukemia-inhibiting factor (human)

emfilermine

facteur d'inhibition leucémique humain

emfilermina

factor inhibidor de leucemia (humano)

SPLPITPVNA	TCAIRHPCHN	NLMNQIRSQL	AQLNGSANAL
FILYYTAQGE	PFNNLDKLC	GPNVTDFPPF	HANGTEKAKL
VELYRIVVYL	GTSLGNITRD	QKILNPSALS	LHSLNATAD
ILRGLLSNVL	CRLCSKYHVG	HVDVTYGPDT	SGKDVQKKK
LGCQLLGKYK	QIIAVLAQAF		

emivirinum

emivirine


6-benzyl-1-(ethoxymethyl)-5-isopropyluracil

émivirine

6-benzyl-1-(éthoxyméthyl)-5-(1-méthyléthyl)pyrimidine-2,4(1*H*,3*H*)-dione

emivirina

6-bencil-1-(etoximetil)-5-isopropiluracilo

 $C_{17}H_{22}N_2O_3$ **entecavirum**


entecavir

9-[(1*S*,3*R*,4*S*)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]guanine

entécavir

2-amino-9-[(1*S*,3*R*,4*S*)-4-hydroxy-3-(hydroxyméthyl)-2-méthylènecyclopentyl]-1,9-dihydro-6*H*-purin-6-one

entecavir

9-[(1*S*,3*R*,4*S*)-4-hidroxi-3-(hidroximetil)-2-metilenociclopentil]guanina $C_{12}H_{15}N_5O_3$ **epitumomabum**

epitumomab

mouse IgG 1 monoclonal antibody which binds the human muc-1 gene product


épitumomab

immunoglobuline G2a, anti-(antigène CD20 humain) (chaîne γ 2a de l'anticorps monoclonal de souris B1R1), dimère du disulfure avec la chaîne λ de l'anticorps monoclonal de souris B1R1


epitumomab	inmunoglobulina G2a, anti-(antígeno CD20 humano) (cadena γ 2a del anticuerpo monoclonal de ratón B1R1), dímero del disulfuro con la cadena λ del anticuerpo monoclonal de ratón B1R1
epratuzumabum epratuzumab	immunoglobulin G (human-mouse monoclonal IMMU-hLL2 γ -chain anti-human antigen CD22), disulfide with human-mouse monoclonal IMMU-hLL2 κ -chain, dimer
épratuzumab	immunoglobuline G, anti-(antigène CD22 humain) (chaîne γ de l'anticorps monoclonal de souris IMMU-hLL2 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris IMMU-hLL2 humanisé
epratuzumab	inmunoglobulina G, anti-(antígeno CD22 humano)(cadena γ del anticuerpo monoclonal humanizado de ratón IMMU-hLL2) dímero del disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón IMMU-hLL2

eptapironum

eptapirone	4-methyl-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-as-triazine-3,5(2 <i>H</i> ,4 <i>H</i>)-dione
eptapirone	4-méthyl-2-[4-[4-(pyrimidin-2-yl)pipérazin-1-yl]butyl]-1,2,4-triazine-3,5(2 <i>H</i> ,4 <i>H</i>)-dione
eptapirona	4-metil-2-[4-[4-(2-pirimidinil)-1-piperazinil]butil]-as-triazina-3,5(2 <i>H</i> ,4 <i>H</i>)-diona
	$C_{16}H_{23}N_7O_2$

**escitalopramum**

escitalopram	(+)-(S)-1-[3-(dimethylamino)propyl]-1-(<i>p</i> -fluorophenyl)-5-phthalanarbonitrile
escitalopram	(+)-(1 <i>S</i>)-1-[3-(diméthylamino)propyl]-1-(4-fluorophényl)-1,3-dihydroisobenzofurane-5-carbonitrile
escitalopram	(+)-(S)-1-[3-(dimetilamino)propil]-1-(<i>p</i> -fluorofenil)-5-ftalancarbonitrilo
	$C_{20}H_{21}FN_2O$



evernimicinum

evernimicin


O-(1*R*)-2,3-*O*-methylene-4-*O*-(6-methyl-β-resorcyloyl)-D-xylopyranosylidene-(1→3-4)-α-L-lyxopyranosyl *O*-2,3,6-trideoxy-3-*C*-methyl-4-*O*-methyl-3-nitro-α-L-*arabino*-hexopyranosyl-(1→3)-*O*-2,6-dideoxy-4-*O*-(3,5-dichloro-6-methoxy-4,2-cresotol)-β-D-*arabino*-hexopyranosyl-(1→4)-*O*-(1*R*)-2,6-dideoxy-D-*arabino*-hexopyranosylidene-(1→3-4)-*O*-6-deoxy-3-*C*-methyl-β-D-mannopyranosyl-(1→3)-*O*-6-deoxy-4-*O*-methyl-β-D-galactopyranosyl-(1→4)-2,6-di-*O*-methyl-β-D-mannopyranoside

évernimicine

O-3-*C*-méthyl-4-*O*-méthyl-3-nitro-2,3,6-tridésoxy-α-L-*arabino*-hexopyranosyl-(1→3)-*O*-4-*O*-(3,5-dichloro-4-hydroxy-2-méthoxy-6-méthylbenzoyl)-2,6-didésoxy-β-D-*arabino*-hexopyranosyl-(1→4)-*O*-(1*R*)-2,6-didésoxy-D-*arabino*-hexopyranosylidène-(1→3-4)-*O*-3-*C*-méthyl-6-désoxy-β-D-mannopyranosyl-(1→3)-*O*-4-*O*-méthyl-6-désoxy-β-D-galactopyranosyl-(1→4)-2,6-di-*O*-méthyl-β-D-mannopyranoside de *O*-(1*R*)-4-*O*-(2,4-dihydroxy-6-méthylbenzoyl)-2,3-*O*-méthylène-D-xylopyranosylidène-(1→3-4)-α-L-lyxopyranosyle

evernimicina

O-2,3,6-tridesoxi-3-*C*-metil-4-*O*-metil-3-nitro-α-L-*arabino*-hexopiranosil-(1→3)-*O*-2,6-didesoxi-4-*O*-(3,5-dicloro-6-metoxi-4,2-cresotol)-β-D-*arabino*-hexopiranosil-(1→4)-*O*-(1*R*)-2,6-didesoxi-D-*arabino*-hexopiranosilideno-(1→3-4)-*O*-6-desoxi-3-*C*-metil-β-D-manopiranosil-(1→3)-*O*-6-desoxi-4-*O*-metil-β-D-galactopiranosil-(1→3)-2,6-di-*O*-metil-β-D-manopiranosido de *O*-(1*R*)-2,3-*O*-metileno-4-*O*-(6-metil-β-resorciloil)-D-xilopiranosilideno-(1→3-4)-α-L-lixopiranosilo

C₇₀H₉₇Cl₂NO₃₈

everolimusum

everolimus


(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-
9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34*a*-hexadecahydro-
9,27-dihydroxy-3-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-(2-hydroxyethoxy)-
3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-
6,8,12,14,20,26-hexamethyl-23,27-epoxy-3*H*-pyrido[2,1-*c*][1,4]=
oxaazacyclohentriacontine-1,5,11,28,29(4*H*,6*H*,31*H*)-pentone

évérolimus

(1*R*,9*S*,12*S*,15*R*,16*E*,18*R*,19*R*,21*R*,23*S*,24*E*,26*E*,28*E*,30*S*,32*S*,35*R*)-1,18-
dihydroxy-12-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-(2-hydroxyéthoxy)-3-
méthoxycyclohexyl]-1-méthyléthyl]-19,30-diméthoxy-15,17,21,23,29,35-
hexaméthyl-11,36-dioxa-4-azatricyclo[30.3.1.0^{4,9}]hexatriaconta-
16,24,26,28-tétraène-2,3,10,14,20-pentone

everolimus

(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-
9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34*a*-hexadecahydro-
9,27-dihidroxi-3-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-(2-hidroxiétoxi)-3-metoxiciclohexil]-
1-metiletil]-10,21-dimetoxi-6,8,12,14,20,26-hexametil-23,27-epoxi-
3*H*-pirido[2,1-*c*][1,4]oxaazaciclohentriacontina-1,5,11,28,29(4*H*,6*H*,31*H*)-
pentona

C₅₃H₈₃NO₁₄**ezlopitantum**

ezlopitant


(2*S*,3*S*)-2-(diphenylmethyl)-3-[(5-isopropyl-2-methoxybenzyl)amino]=
quinuclidine

ezlopitant

(2*S*,3*S*)-2-(diphénylméthyl)-*N*-[2-méthoxy-5-(1-méthyléthyl)benzyl]-
1-azabicyclo[2.2.2]octan-3-amine

ezlopitant

(2*S*,3*S*)-2-(difenilmetil)-3-[(5-isopropil-2-metoxibencil)amino]quinuclidina

$C_{31}H_{38}N_2O$ **fiduxosinum**

fiduxosin


8-phenyl-3-[4-[(3a*R*,9b*R*)-1,3a,4,9b-tetrahydro-9-methoxy[1]benzopyrano=[3,4-*c*]pyrrol-2(3*H*)-yl]butyl]pyrazino[2',3':4,5]thieno[3,2-*d*]pyrimidine-2,4(1*H*,3*H*)-dione

fiduxosine

3-[4-[(3a*R*,9b*R*)-9-méthoxy-1,3a,4,9b-tétrahydro[1]benzopyrano[3,4-*c*]pyrrol-2(3*H*)-yl]butyl]-8-phénylpyrazino[2',3':4,5]thiéno[3,2-*d*]pyrimidine-2,4(1*H*,3*H*)-dione

fiduxosina

8-fenil-3-[4-[(3a*R*,9b*R*)-1,3a,4,9b-tetrahydro-9-metoxi[1]benzopirano[3,4-*c*]pirrol-2(3*H*)-il]butil]pirazino[2',3':4,5]tieno[3,2-*d*]pirimidina-2,4(1*H*,3*H*)-diona

 $C_{30}H_{29}N_5O_4S$ **figopitantum**

figopitant


(*S*)-*N*-[bis(3,5-trifluoromethyl)phenethyl]-4-(cyclopropylmethyl)-*N*-methyl- α -phenyl-1-piperazineacetamide

figopitant

(2*S*)-*N*-[2-[3,5-bis(trifluorométhyl)phényl]éthyl]-2-[4-(cyclopropylméthyl)=pipérazin-1-yl]-*N*-méthyl-2-phénylacétamide

figopitant

(*S*)-*N*-[bis(3,5-trifluorometil)fenetil]-4-(ciclopropilmetil)-*N*-metil- α -fenil-1-piperazinaacetamida

 $C_{27}H_{31}F_6N_3O$ 

implitapidum

implitapide


(αS)- α -[α -(2,4-diméthyl-9*H*-pyrido[2,3-*b*]indol-9-yl)-*p*-tolyl]-*N*-[(αR)- α -(hydroxyméthyl)benzyl]cyclopentaneacetamide

implitapide

(2*S*)-2-cyclopentyl-2-[4-[(2,4-diméthyl-9*H*-pyrido[2,3-*b*]indol-9-yl)méthyl]phényl]-*N*-[(1*R*)-2-hydroxy-1-phényléthyl]acétamide

implitapida

(αS)- α -[α -(2,4-diméthyl-9*H*-pyrido[2,3-*b*]indol-9-yl)-*p*-tolyl]-*N*-[(αR)- α -(hydroxyméthyl)benzyl]cyclopentanoacetamida

C₃₅H₃₇N₃O₂**irampanelum**

irampanel


5-[*o*-[2-(diméthylamino)éthoxy]phényl]-3-phényl-1,2,4-oxadiazole

irampanel

N,N-diméthyl-2-[2-(3-phényl-1,2,4-oxadiazol-5-yl)phénoxy]éthanamine

irampanel

5-[*o*-[2-(diméthylamino)éthoxy]fénil]-3-fénil-1,2,4-oxadiazol

C₁₈H₁₉N₃O₂**irofulvenum**

irofulven



(*R*)-6'-hydroxy-3'-(hydroxyméthyl)-2',4',6'-triméthylspiro[cyclopropane-1,5'-[5*H*]indén]-7'(6'*H*)-one

irofulvène

(6'*R*)-6'-hydroxy-3'-(hydroxyméthyl)-2',4',6'-triméthylspiro[cyclopropane-1,5'-[5*H*]indén]-7'(6'*H*)-one

irofulveno

(*R*)-6'-hidroxi-3'-(hidroximetil)-2',4',6'-trimetilspiro[ciclopropano-1,5'-[5*H*]indén]-7'(6'*H*)-ona

**itriglumidum**

itriglumide



(R)-2'--(8-azaspiro[4.5]dec-8-ylcarbonyl)-4',6'-dimethyl-3-(1-naphthyl)glutaranilic acid

itriglumide

acide (3R)-5-[[2-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4,6-diméthylphényl]amino]-3-(naphtalén-1-yl)-5-oxopentanoïque

itriglumida

ácido (R)-2'-(8-azaspiro[4.5]dec-8-ilcarbonil)-4',6'-dimetil-3-(1-naftil)glutaranílico

**laniceminum**

lanicemine


(+)-2-[(S)-β-aminophenethyl]pyridine

lanicémine

(+)-(1S)-1-phényl-2-(pyridin-2-yl)éthanamine

lanicemina

(+)-2-[(S)-β-aminofenetil]piridina

**lusaperidonum**

lusaperidone


3-[2-(3,4-dihydrobenzofuro[3,2-c]pyridin-2(1H)-yl)ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

lusapéridone

3-[2-(3,4-dihydrobenzofuro[3,2-c]pyridin-2(1H)-yl)éthyl]-2-méthyl-4H-pyrido[1,2-a]pyrimidin-4-one

lusaperidona

3-[2-(3,4-dihydrobenzofuro[3,2-c]piridin-2(1H)-il)etil]-2-metil-4H-pirido[1,2-a]pirimidin-4-ona

C₂₂H₂₁N₃O₂**metreleptinum**

metreleptin

N-methionylleptin (human)

métréleptine

N-méthionylleptine humaine

metreleptina

N-metionileptina (humana)C₇₁₄H₁₁₆₇N₁₉₁O₂₂₁S₆

M

VPIQKVQDDT	KTLIKTIVTR	INDISHTQSV	SSKQKVTGLD
FIPGLHPILT	LSKMDQTLAV	YQQILTSMPS	RNVIQISNDL
ENLRDLLHVL	AFSKSCHLPW	ASGLETLDL	GGVLEASGYS
TEVVALSRLQ	GSLQDMLWQL	DLSPGC	

mitumomabum

mitumomab

immunoglobulin G2b (mouse monoclonal BEC2 γ2b-chain anti-GD3 ganglioside), disulfide with mouse monoclonal BEC2 κ-chain, dimer

mitumomab

immunoglobuline G2b, anti-(ganglioside GD3) (chaîne γ2b de l'anticorps monoclonal de souris BEC2), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris BEC2

mitumomab

inmunoglobulina G2b, anti-(gangliósido GD3) (cadena γ2b del anticuerpo monoclonal de ratón BEC2) dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón BEC2

motexafinum

motexafin


9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanol

motéxafine

3,3'-[9,10-diéthyl-20,21-bis[2-[2-(2-méthoxyéthoxy)éthoxy]éthoxy]-4,15-diméthyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosène-5,14-diyl]dipropan-1-ol

motexafina

9,10-dietil-20,21-bis[2-[2-(2-metoxietoxi)etoxi]etoxi]-4,15-dimetil-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacicloeicosina-5,14-dipropanol

$C_{48}H_{67}N_5O_{10}$ **nebostinelum**

nebostinel


(S)-4-amino-N-(4,4-dimethylcyclohexyl)glutaramic acid

nébostinel

acide (4S)-4-amino-5-[(4,4-diméthylcyclohexyl)amino]-5-oxopentanoïque

nebostinel

ácido (S)-4-amino-N-(4,4-dimetilciclohexil)glutarámico

 $C_{13}H_{24}N_2O_3$ **onerceptum**

onercept


glycoprotein TNF-BP (tumor necrosis factor-binding protein) (human disulfide variant 1)

onercept

20-180-récepteur 1 humain du facteur de nécrose tumorale, protéine glycosylée (partie du domaine extracellulaire)

onercept

glicoproteína TNF-BP (proteína de unión al factor de necrosis tumoral)(disulfuro de la variante 1 humana)

 $C_{753}H_{1156}N_{228}O_{247}S_{25}$ 

* glycosylation sites
 * sites de glycosylation
 * posiciones de glicosilación

pegvisomantum pegvisomant	18-L-aspartic acid-21-L-asparagine-120-L-lysine-167-L-asparagine-168-L-alanine-171-L-serine-172-L-arginine-174-L-serine-179-L-threonine growth hormone (human), reaction product with polyethylene glycol
pegvisomant	[18-acide L-aspartique-21-L-asparagine-120-L-lysine-167-L-asparagine-168-L-alanine-171-L-sérine-172-L-arginine-174-L-sérine-179-L-thréonine] hormone humaine de croissance combinée à du polyéthylène glycol
pegvisomant	producto de reacción con polietilenglicol de la 18-ácido-L-aspartico 21-L-asparagina-120-L-lisina-167-L-asparagina-168-L-alanina-171-L-serina-172-L-arginina-174-L-serina-179-L-treoninahormona del crecimiento (humana)


```

*
*FTIPLSRLEF  DNAMLRADRL  NQLAFDTYQE  FEEAYIPKEQ
KYSFLQNPQT  SLCFSESIPT  PSNREETQQK  SNLELLRISL
LLIQSWLEPV  QFLRSVFANS  LVYGASDSNV  YDLLKDLEEK
IQTLMGRLED  GSPRTGQIFK  QTYSKFDTNS  HNDDALLKNY
GLLYCFNADM  SRVSTFLRTV  QCRSVEGSCG  F


```

* pegylation sites
 * sites de pégylation
 * posiciones de pegilación

perflexanum perflexane	tetradecafluorohexane
perflexane	tétradécafluorohexane
perflexano	tetradecafluorohexano

C₆F₁₄

perflutrenum perflutren	octafluoropropane
perflutrène	octafluoropropane
perflutreno	octafluoropropano

C₃F₈

pinokalantum


pinokalant

(±)-3,4-dihydro-6,7-dimethoxy-α-phenyl-*N,N*-bis(2,3,4-trimethoxyphenethyl)-1-isoquinolineacetamide

pinokalant

(2*RS*)-2-(6,7-diméthoxy-3,4-dihydroisoquinoléin-1-yl)-2-phényl-*N,N*-bis[2-(2,3,4-triméthoxyphényl)éthyl]acétamide

pinokalant

(±)-3,4-dihidro-6,7-dimetoxi-α-fenil-*N,N*-bis(2,3,4-trimetoxifenetil)-1-isoquinolinacetamidaC₄₁H₄₈N₂O₉**posaconazolum**


posaconazole

4-[*p*-[4-[*p*-[[*(3R,5R)*]-5-(2,4-difluorophenyl)tetrahydro-5-(1*H*-1,2,4-triazol-1-ylmethyl)-3-furyl]methoxy]phenyl]-1-piperazinyl]phenyl]-1-[(1*S,2S*)-1-ethyl-2-hydroxypropyl]-Δ²-1,2,4-triazolin-5-one

posaconazole

4-[4-[4-[4-[[*(3R,5R)*]-5-(2,4-difluorophényl)-5-(1*H*-1,2,4-triazol-1-ylméthyl)=tétrahydrofuran-3-yl]méthoxy]phényl]pipérazin-1-yl]phényl]-2-[(1*S,2S*)-1-éthyl-2-hydroxypropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one

posaconazol

4-[*p*-[4-[*p*-[[*(3R,5R)*]-5-(2,4-difluorofenil)tetrahidro-5-(1*H*-1,2,4-triazol-1-ilmetil)-3-furil]metoxi]fenil]-1-piperazinil]fenil]-1-[(1*S,2S*)-1-etil-2-hidroxiopropil]-D²-1,2,4-triazolin-5-onaC₃₇H₄₂F₂N₈O₄

prinomastatum

prinomastat



(S)-2,2-dimethyl-4-[[p-(4-pyridyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxylic acid

prinomastat

(3S)-N-hydroxy-2,2-diméthyl-4-[[4-(pyridin-4-yloxy)phényl]sulfonyl]=thiomorpholine-3-carboxamide

prinomastat

ácido (S)-2,2-dimetil-4-[[p-(4-piridiloxi)fenil]sulfonyl]-3-tiomorfolinacarbohidroxámico

**pumafentrinum**

pumafentrine



(-)-p-[(4aR*,10bS*)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N,N-diisopropylbenzamide

pumafentrine

(-)-4-[(4aR*,10bS*)-9-éthoxy-8-méthoxy-2-méthyl-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphtyridin-6-yl]-N,N-bis(1-méthyléthyl)benzamide

pumafentrina

(-)-p-[(4aR*,10bS*)-9-etoxi-1,2,3,4,4a,10b-hexahidro-8-metoxi-2-metilbenzo[c][1,6]naftiridina-6-il]-N,N-diisopropilbenzamida

or enantiomer
ou énantiomère
o enantiómero**relcovaptanum**

relcovaptan


(2S)-1-[[[(2R,3S)-5-chloro-3-(o-chlorophenyl)-1-[(3,4-dimethoxyphenyl)=sulfonyl]-3-hydroxy-2-indolyl]carbonyl]-2-pyrrolidinecarboxamide

relcovaptan

(2S)-1-[[[(2R,3S)-5-chloro-3-(2-chlorophényl)-1-[(3,4-diméthoxyphényl)=sulfonyl]-3-hydroxy-2,3-dihydro-1H-indol-2-yl]carbonyl]pyrrolidine-2-carboxamide

relcovaptán

(2S)-1-[[[(2R,3S)-5-cloro-3-(o-clorofenil)-1-[(3,4-dimetoxifenil)sulfonyl]-3-hidroxi-2-indolil]carbonil]-2-pirrolidinacarboxamida

$C_{28}H_{27}Cl_2N_3O_7S$ **repiferminum**

repifermin

33-172-keratinocyte growth factor 2 (human)

répiférmine

33-172-facteur 2 humain de croissance du kératinocyte

repifermina

33-172-factor 2 de crecimiento de queratinocitos (humano)

 $C_{723}H_{1131}N_{209}O_{204}S_5$

SYNHLQGDVR	WRKLFSEFTKY	FLKIEKNGKV	SGTKKENCYPY
SILEITSVEI	GVVAVKAINS	NYYLAMNKKG	KLYGSKEFNN
DCKLKERIEE	NGYNTYASFN	WQHNGRQMYV	ALNGKGAPRR
GQKTRRKNTS	AHFLPMVVHS		

resiquimodum


resiquimod

4-amino-2-(ethoxymethyl)- α,α -dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol

résiquimod

1-[4-amino-2-(éthoxyméthyl)-1*H*-imidazo[4,5-*c*]quinoléin-1-yl]-2-méthylpropan-2-ol

resiquimod

4-amino-2-(etoximetil)- α,α -dimetil-1*H*-imidazo[4,5-*c*]quinolina-1-etanol $C_{17}H_{22}N_4O_2$ **risarestatum**

risarestat


($\pm$)-5-[3-ethoxy-4-(pentyloxy)phenyl]-2,4-thiazolidinedione

risarestat

(5*RS*)-5-[3-éthoxy-4-(pentyloxy)phényl]thiazolidine-2,4-dione

risarestat

(±)-5-[3-etoxy-4-(pentiloxi)fenil]-2,4-tiazolidinadiona

 $C_{16}H_{21}NO_4S$ **rubitecanum**

rubitecan


9-nitrocamptothecin

rubitécan

(4*S*)-4-éthyl-4-hydroxy-10-nitro-1,12-dihydro-14*H*-pyrano[3',4':6,7]=indolizino[1,2-*b*]quinoléine-3,14(4*H*)-dione

rubitecán

9-nitrocamptotecina

 $C_{20}H_{15}N_3O_6$ **sulamserodum**


sulamserod

N-[2-[4-[2-[(8-amino-7-chloro-1,4-benzodioxan-5-yl)carbonyl]ethyl]piperidino]ethyl]methanesulfonamide

sulamsérod

N-[2-[4-[3-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-3-oxopropyl]pipéridin-1-yl]éthyl]méthanesulfonamide

sulamserod

N-[2-[4-[2-[(8-amino-7-cloro-1,4-benzodioxan-5-il)carbonil]etil]piperidino]=etil]metanosulfonamida $C_{19}H_{28}ClN_3O_5S$ **tanomastatum**

tanomastat


(S)-3-[(4'-chloro-4-biphenyl)carbonyl]-2-[(phenylthio)methyl]propionic acid

tanomastat

acide (2*S*)-4-(4'-chlorobiphényl-4-yl)-4-oxo-2-[(phénylsulfanyl)méthyl]=butanoïque

tanomastat

ácido (2S)-4-(4'-clorobifenil-4-il)-4-oxo-2-[(fenilsulfanilo)metil]butanoico

 $C_{23}H_{19}ClO_3S$ **tebipenemum**


tebipenem

(+) -hydroxymethyl (4*R*,5*S*,6*S*)-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[1-(2-thiazolin-2-yl)-3-azetidiny]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate, 2-pivalate

tébipénem

(+) - (4*R*,5*S*,6*S*)-3-[[1-(4,5-dihydrothiazol-2-yl)azetidín-3-yl]sulfany]-6-[(1*R*)-1-hidroxiétil]-4-méthyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ène-2-carboxylate de [(2,2-diméthylpropanoyl)oxy]méthyle

tebipenem

2-pivalato y (4*R*,5*S*,6*S*)-6-[(1*R*)-1-hidroxiétil]-4-metil-7-oxo-3-[[1-(2-tiazolin-2-il)-3-azetidín]tio]-1-azabíciclo[3.2.0]hept-2-eno-2-carboxilato de metileno $C_{22}H_{31}N_3O_6S_2$ **tenofovirum**


tenofovir

[[*(R)*]-2-(6-amino-9*H*-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid

ténofovir

acide [[(1*R*)-2-(6-amino-9*H*-purin-9-yl)-1-méthyléthoxy]méthyl]phosphonique

tenofovir

ácido [[(*R*)-2-(6-amino-9*H*-purin-9-il)-1-metiletoxi]metil]fosfónico $C_9H_{14}N_5O_4P$ 

tiplimotidum

tiplimotide

D-alanyl-L-lysyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-leucyl-L-phenylalanyl-L-alanyl-L-asparaginyll-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-threonyl-L-prolinamide

tiplimotide

D-alanyl-L-lysyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-leucyl-L-phénylalanyl-L-alanyl-L-asparaginyll-L-isoleucyl-L-valyl-L-thréonyl-L-prolyl-L-arginyl-L-thréonyl-L-prolinamide

tiplimotida

D-alanil-L-lisil-L-prolil-L-valil-L-valil-L-histidil-L-leucil-L-fenilalanil-L-alanil-L-asparaginil-L-isoleucil-L-valil-L-treonil-L-prolil-L-arginil-L-treonil-L-prolinamida

 $C_{87}H_{143}N_{25}O_{20}$ D-Ala—Lys—Pro—Val—Val—His—Leu—Phe—Ala—Asn—
10Ile—Val—Thr—Pro—Arg—Thr—Pro—NH₂**valrocedidum**


valrocedime

N-(carbamoylmethyl)-2-propylvaleramide

valrocéme

N-(2-amino-2-oxoéthyl)-2-propylpentanamide

valrocedida

N-(carbamoilmetil)-2-propilvaleramida $C_{10}H_{20}N_2O_2$ **vardenafilum**


vardenafil

1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-*f*]-*as*-triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-4-ethylpiperazine

vardénafil

2-[2-éthoxy-5-[(4-éthylpipérazin-1-yl)sulfonyl]]phényl]-5-méthyl-7-propylimidazo[5,1-*f*][1,2,4]triazin-4(3*H*)-one

vardenafil

1-[[3-(3,4-dihidro-5-metil-4-oxo-7-propilimidazo[5,1-*f*]-*as*-triazin-2-il)-4-etoxifenil]sulfonil]-4-etilpiperazina $C_{23}H_{32}N_6O_4S$ 

vofopitantum

vofopitant


(2*S*,3*S*)-3-[[2-methoxy-5-[5-(trifluoromethyl)-1*H*-tetrazol-1-yl]benzyl]amino]-2-phenylpiperidine

vofopitant

(2*S*,3*S*)-*N*-[2-méthoxy-5-[5-(trifluorométhyl)-1*H*-tétrazol-1-yl]benzyl]-2-phénylpipéridin-3-amine

vofopitant

(2*S*,3*S*)-3-[[2-metoxi-5-[5-(trifluorometil)-1*H*-tetrazol-1-il]bencil]amino]-2-fenilpiperidina

 $C_{21}H_{23}F_3N_6O$ 

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Nonproprietary Names (Rec. INN): List 43

Dénominations communes internationales recommandées (DCI Rec.): Liste 43

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 43

(WHO Drug Information, Vol. 14, No. 1, 2000)

p. 50 **eledoisinum**

eledoïsine

remplacer le nom par le suivant:

éledoïsine

p. 57 **idremcinalum**

idremcinal

remplacer le nom chimique par le suivant:

(2*R*,3*R*,4*S*,5*R*,8*R*,9*S*,10*S*,11*R*,12*R*)-5-éthyl-3,4-dihydroxy-2,4,8,10,12,14-hexaméthyl-9-[(3-*C*-méthyl-3-*O*-méthyl-2,6-didésoxy- α -L-ribo-hexopyranosyl)oxy]-11-[[3-[méthyl(1-méthyléthyl)amino]-3,4,6-tridésoxy- β -D-xylo-hexopyranosyl]oxy]-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-én-7-one

p. 59 **lasofoxifenum**

lasofoxifène

remplacer le nom chimique par le suivant:

(-)-(5*R**,6*S**)-6-phényl-5-[4-[2-(pyrrolidin-1-yl)éthoxy]phényl]-5,6,7,8-tétrahydronaphtalén-2-ol

p. 64 **pimecrolimusum**

pimécrolimus

remplacer le nom chimique par le suivant:

(1*R*,9*S*,12*S*,13*R*,14*S*,17*R*,18*E*,21*S*,23*S*,24*R*,25*S*,27*R*)-12-[(*E*)-2-[(1*R*,3*R*,4*S*)-4-chloro-3-méthoxycyclohexyl]-1-méthyléthényl]-17-éthyl-1,14-dihydroxy-23,25-diméthoxy-13,19,21,27-tétraméthyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ène-2,3,10,16-tétrone

p. 66 **sarakalimum**

sarakalim

remplacer le nom chimique par le suivant:

N-[[2,2-diméthyl-4-(2-oxopyridin-1(2*H*)-yl)-6-(trifluorométhyl)-2*H*-1benzopyran-3-yl]méthyl]-*N*-hydroxyacétamide

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* ont été publiés avec la liste 81 des DCI proposées et seront, à nouveau, publiés avec la prochaine liste des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.

